The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: -8.00 (-2.63%)
Spread: 4.00 (1.356%)
Open: 292.00
High: 298.00
Low: 292.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Hutchmed in Macau boost; UP Global success in Germany

Tue, 01st Mar 2022 20:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval to market fruquintinib, an inhibitor of vascular endothelial growth factor receptors, in Macau. Drugs of this type are often used to treat cancer.

----------

UP Global Sourcing Holdings PLC - Oldham, Greater Manchester-based consumer brands owner - Petra brand receives first "substantial" order from a German hypermarket retailer. "Petra, the group's recently acquired German kitchen electrical brand, is well recognised in the German market and enjoys a reputation for quality and design innovation," UP Global says. Deal is worth EUR1 million.

----------

JPMorgan Russian Securities PLC - Russia-focused investor - Says 49% of portfolio comprises of locally-listed stocks it is currently not allowed to trade in due to restrictions. Holds shares in Russian state-backed VTB Bank amounting to 1.9% of investor's portfolio. Company manager monitoring impact of sanctions and also waives management fee. Will not buyback shares during uncertain market conditions and says sanctions restrict ability to pay further dividends. "It remains the company's intention to resume quarterly dividend payments once circumstances permit," JPMorgan Russian says.

----------

Puma VCT 13 PLC - venture capital trust - Exercises over-allotment facility linked with GBP25 million fundraise. To raise further GBP5 million.

----------

Bango PLC - Cambridge-based mobile commerce company - Begins trading on OTC Markets Group's OTCQX Best Market. "Trading on OTCQX will further increase the visibility and accessibility of Bango to North American investors. OTCQX supports more transparent quotation and trading of Bango ordinary shares in US dollars during trading hours in the United States, allowing easier access for investors who prefer securities that trade domestically in US dollars," Bango adds.

----------

Omega Diagnostics Group PLC - Alva, Scotland-based medical diagnostics - Says total amount raised from fundraise is GBP5.5 million. It had planned to raise up to GBP7 million.

----------

DeepMatter Group PLC - Glasgow, Scotland-based digital chemistry data company - Signs collaboration deal with Standigm Inc, a workflow artificial intelligence drug discovery company, based in South Korea. "The first stage of the agreement is expected to generate revenues of GBP233,000. The group is now actively working towards broadening the scope of the agreement in the three-year term," DeepMatter says. "DeepMatter will provide access to its proprietary data and algorithms via its unique data and laboratory integration platform."

----------

7digital Group PLC - London-based music licensing provider - Signs deal with existing B2B music streaming service customer worth at least EUR2.2 million over three-year period. "The company has been providing services to the customer since 2016, with contract renewals on an annual basis. This latest contract expands the relationship to a long-term agreement, providing greater visibility over revenue. The company also expects the value of the contract to increase as the fast-growing customer seeks to expand its brand into further territories, which would require further licence agreements with 7digital," 7digital says.

----------

Mobile Streams PLC - London-based mobile content provider - Says monthly revenue now exceeds USD150,000. "In addition, the company has commenced the process of uploading its content, including Esports, to the Huawei App gallery and anticipates once successful these will be made available across the Huawei handset user base," Mobile Streams adds.

----------

Hardide PLC - Oxfordshire-based advanced surface coating technology developer - Delivers first production set of coated turbine blades for Ansaldo Energia Spa, a manufacturer of steam and gas turbines. "These blades are to be installed in advanced gas turbine engines with high operational flexibility that cut CO2 emissions and operational costs in a very demanding market. More orders for this application are expected to be placed during 2022," Hardide adds.

----------

Getech Group PLC - Leeds-based provider of geoscience data - Wins GBP1.2 million deals for its geoscience data and energy software products. "The contracts, which include annual and multi-year licences with new and existing customers, add to Getech's recurring revenue and orderbook," company says.

----------

Journeo PLC - Leicestershire-based transport information systems and technical services - Gets GBP2.1 million order from City of Edinburgh to upgrade real-time outdoor passenger display systems. "The purchase order includes the supply and support of over 400 optically bonded new displays as part of the second phase of a 5 year GBP4.8 million services and support contract," Journeo says.

----------

AFC Energy PLC - Cranleigh, England-based hydrogen power generation technologies provider - Says it and partner Acciona agree to deploy AFC's first hybrid fuel cell system in Spain.

----------

Phoenix Copper Ltd - British Virgin Islands-based base and precious metals production and exploration company - Under environmental, social and governance plans, Phoenix is to create the Konnex Community Advisory Team. This is to build "meaningful relationships" in communities near Empire State mine in Idaho, US.

----------

Beowulf Mining PLC - developing Kallak iron ore mine in Sweden and Aitolampi graphite mine in Finland - Invests further GBP200,000 in Vardar Minerals Ltd. Increases stake to 51% from 49%. Also notes talks with Vardar's management for final plan for drilling, including at Wolf Mountain, which has lead and zinc targets. "Drilling could start in the next 1-2 months and Beowulf would provide the funding," Beowulf adds.

----------

Mila Resources PLC - London-based gold company focused on Australia - Second drill hole at Kathleen Valley, Australia hosts sulphides akin to adjacent Bellevue gold discoveries. "Drilling continues to define a wide coherent zone of mineralisation which is open at depth and maintains a very-linear consistent zone," Mila says.

----------

88 Energy Ltd - Australia-based oil explorer in US state of Alaska - Says mobilisation of Arctic Fox rig to Merlin-2 appraisal well drilling location is now complete. "Pre-spud operations are continuing and now entering the final phase. The Merlin-2 spud date is scheduled for the week commencing 7 March 2022," 88 adds.

----------

Cloudbreak Discovery PLC - London-based natural resource project generator - Raises GBP1.5 million in share placing, to advance various project generation initiatives and for working-capital purposes. Cloudbreak places 20 million shares at 7.50p each, representing a 20% discount to Monday's closing price of 10.22p.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
12 Sep 2023 11:26

Hutchmed reports progress on two oncology fronts

(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.

Read more
12 Sep 2023 10:26

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL.

Read more
29 Aug 2023 13:38

Hutchmed tumour therapy candidate gets breakthrough designation

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to its investigational drug savolitinib.

Read more
29 Aug 2023 09:30

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.

Read more
21 Aug 2023 08:46

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.

Read more
21 Aug 2023 08:24

Hutchmed meets all endpoints in platelet disorder treatment trial

(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.

Read more
31 Jul 2023 12:47

Hutchmed swings to profit after "sharpening goals and priorities"

(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.

Read more
24 Jul 2023 15:46

UK earnings, trading statements calendar - next 7 days

Tuesday 25 July 
City of London Investment Group PLCTrading Statement
Compass Group PLCTrading Statement
Croda International PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Greencore Group PLCTrading Statement
Hummingbird Resources PLCTrading Statement
MITIE Group PLCTrading Statement
Paragon Banking Group PLCTrading Statement
Reach PLCHalf Year Results
Smart Metering Systems PLCTrading Statement
Tristel PLCTrading Statement
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Unite Group PLCHalf Year Results
Wednesday 26 July 
Aptitude Software Group PLCHalf Year Results
Breedon Group PLCHalf Year Results
Conduit Holdings LtdHalf Year Results
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
FRP Advisory Group PLCFull Year Results
Gresham Technologies PLCHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Rathbones Group PLCHalf Year Results
Revolution Bars Group PLCTrading Statement
Rio Tinto PLCHalf Year Results
Science Group PLCHalf Year Results
Van Elle Holdings PLCFull Year Results
Thursday 27 July 
Allianz Technology Trust PLCHalf Year Results
Antofagasta PLCHalf Year Results
Capital & Regional PLCHalf Year Results
Card Factory PLCTrading Statement
Checkit PLCTrading Statement
Drax Group PLCHalf Year Results
Deliveroo PLCHalf Year Results
Derwent London PLCHalf Year Results
Entain PLCHalf Year Results
Greencoat UK Wind PLCHalf Year Results
Global Connectivity PLCHalf Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Lancashire Holdings LtdHalf Year Results
Mitchells & Butlers PLCTrading Statement
OSB Group PLCHalf Year Results
Persimmon PLCHalf Year Results
Petrofac LtdHalf Year Results
Redcentric PLCFull Year Results
S&U PLCTrading Statement
Savills PLCHalf Year Results
Secure Trust Bank PLCHalf Year Results
Spirax-Sarco Engineering PLCHalf Year Results
Videndum PLCHalf Year Results
Wheaton Precious Metals CorpHalf Year Results
Friday 28 July 
AIB Group PLCHalf Year Results
GCP Infrastructure Investments LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Jardine Matheson Holdings LtdHalf Year Results
NatWest Group PLCHalf Year Results
PayPoint PLCFull Year Results
PayPoint PLCTrading Statement
Standard Chartered PLCHalf Year Results
YouGov PLCTrading Statement
Monday 31 July 
Hutchmed (China) LtdHalf Year Results
Pearson PLCHalf Year Results
Pod Point Group Holdings PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Jul 2023 14:14

IN BRIEF: Hutchmed progresses fruquintinib designation and testing

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.

Read more
10 Jul 2023 12:58

Hutchmed launches new phase one study in China

(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).

Read more
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.